The Aerogen(®) Solo Is an Alternative to the Small Particle Aerosol Generator (SPAG-2) for Administration of Inhaled Ribavirin

Respiratory syncytial virus (RSV) is associated with adverse outcomes among immunocompromised patients. Inhaled ribavirin has been shown to improve mortality rates. The Small-Particle Aerosol Generator delivery system (SPAG-2) is the only FDA-cleared device to deliver inhaled ribavirin. However, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Dallas, Ronald H., Rains, Jason K., Wilder, Keith, Humphrey, William, Cross, Shane J., Ghafoor, Saad, Brazelton de Cardenas, Jessica N., Hayden, Randall T., Hijano, Diego R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760766/
https://www.ncbi.nlm.nih.gov/pubmed/33260359
http://dx.doi.org/10.3390/pharmaceutics12121163
Descripción
Sumario:Respiratory syncytial virus (RSV) is associated with adverse outcomes among immunocompromised patients. Inhaled ribavirin has been shown to improve mortality rates. The Small-Particle Aerosol Generator delivery system (SPAG-2) is the only FDA-cleared device to deliver inhaled ribavirin. However, it is difficult to set up and maintain. We developed a method for delivery of this medication using the vibrating mesh nebulizer (Aerogen(®)). We did not observe any adverse events with this method.

Ejemplares similares